TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).
On September 25, 2025, Tiziana Life Sciences announced plans to advance its second asset, TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody. This decision comes amid increased industry interest in IL-6 pathway therapies, highlighted by Novartis’ recent acquisition of Tourmaline Bio. Tiziana aims to develop TZLS-501 as a monotherapy or in combination with other agents, while continuing to focus on its lead program, intranasal foralumab. The advancement of TZLS-501 is seen as a strategic move to capitalize on the growing importance of IL-6 therapeutics in treating systemic inflammation and related diseases.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company specializes in alternative routes of immunotherapy, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody currently in clinical development. Tiziana’s innovative approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods.
Average Trading Volume: 373,730
Technical Sentiment Signal: Buy
Current Market Cap: $219.6M
For detailed information about TLSA stock, go to TipRanks’ Stock Analysis page.